An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

About this trial

Last updated a year ago

Study ID

QLS-010

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

Accepting

45 to 79 Years

All Sexes

Trial Timing

Ended a year ago

What is this trial about?

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

What are the participation requirements?

Inclusion Criteria

* Provide voluntary, written, informed consent to participate in the study

* Agree to provide a valid cell phone number and are willing to receive communications through text.

* Healthy adults 45 - 79 years of age Can read and write English

* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.

* Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.

* Willing to complete questionnaires, records, and diaries associated with the study.

Exclusion Criteria

* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial

* Known food intolerances/allergy to any ingredients in the product

* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer

* Having had a significant cardiovascular event in the past 6 months

* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines

* On immunosuppressive therapy

* Individuals who were deemed incompatible with the test protocol

* Adults lacking capacity to consent